• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA warns on Covidien’s liquid embolic system following 9 patient deaths

FDA warns on Covidien’s liquid embolic system following 9 patient deaths

July 10, 2012 By MassDevice staff

Covidien logo

The FDA issued a safety alert after receiving reports of more than 100 adverse events, including 9 patient deaths, that may have been caused by Onyx brain blood vessel plugs made by Covidien (NYSE:COV) subsidiary ev3 Inc.

The Massachusetts-based device maker hasn’t issued a recall on the Onyx product, a liquid embolic system designed to block blood flow to problem blood vessels before surgical removal, but the FDA approved new device labeling indicating the risk of "catheter entrapment," in which the device’s delivery catheter becomes stuck in brain.

The Onyx product is delivered to the brain via catheter, and since Jan. 1, 2005, the FDA has received 100 reports of the catheters becoming stuck in patients’ brains.

"In at least 54 of these cases, it was not possible to remove the catheter, so part of the catheter and the implanted Onyx material remained implanted in the patient," according to the FDA warning.

The device, made by Covidien subsidiary ev3 Inc., is a spongy material that hardens when it comes into contact with blood. The Onyx liquid is injected through the catheter to the brain vessel site, and entrapment occurred when the catheter became stuck in the hardened Onyx material, according to the report.

"The clinical data submitted by the manufacturer prior to marketing included cases where the delivery catheter was difficult to remove, but in all cases the catheter was removed without any adverse patient events," the federal watchdog agency noted. "The original product labeling did not reflect the risks related to catheter entrapment but new labeling will include these risks as well as recommendations to help minimize that risk."

Catheter entrapment isn’t likely to hinder a physician’s ability to surgically remove problem brain vessels, but neither the Onyx device or the catheter delivery system were intended to remain in the brain for long periods of time, the FDA cautioned.

"Complications associated with catheter entrapment can be serious. The most serious complications include hemorrhage and death," according to the report. "Other complications include migration of the Onyx plug or catheter fragment to other parts of the body. Patients with catheter entrapment may need to take antithrombotic drugs to prevent blood clots around the catheter, and may need to undergo one or more imaging procedures to locate a piece of the catheter and Onyx plug, increasing their exposure to radiation."

The agency warned surgeons to avoid aggressive attempts to remove stuck catheters as that could result in catheter breakage or brain hemorrhage. The FDA asked surgeons to note the manufacturers instructions for removing an entrapped catheter, and to report any new incidents for ongoing monitoring.

Covidien representatives did not immediately return requests for comment.

Filed Under: News Well Tagged With: Covidien, ev3 Inc., Neurovascular repair, Warning Letter

More recent news

  • Medtronic escapes $106.5M payment in Colibri TAVR patent suit after court overturns jury verdict
  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy